Lexicare Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 31-12-2024
- Paid Up Capital ₹ 0.10 M
as on 31-12-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 31-12-2024
- Revenue 93.00%
(FY 2022)
- Profit 67.77%
(FY 2022)
- Ebitda 27.01%
(FY 2022)
- Net Worth 38.11%
(FY 2022)
- Total Assets 80.89%
(FY 2022)
About Lexicare Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Rajeshbhai Mavani, Chetankumar Gorasiya, and Sureshkumar Gorasiya serve as directors at the Company.
- CIN/LLPIN
U24230GJ2011PTC064061
- Company No.
064061
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Feb 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Lexicare Pharma Private Limited offer?
Lexicare Pharma Private Limited offers a wide range of products and services, including Cosmetics, Skin Care Cosmetics, Pharmaceutical Syrup, Dry Syrups, Antacid Drugs, Rabeprazole Tablets, Allopathic Cough Syrup, Ambroxol Hydrochloride Syrup, Dextromethorphan Cough Syrup, Digestive System Drugs & Medicines.
Who are the key members and board of directors at Lexicare Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeshbhai Mavani  | Director | 17-Feb-2011 | Current |
| Chetankumar Gorasiya | Director | 17-Feb-2011 | Current |
| Sureshkumar Gorasiya | Director | 17-Feb-2011 | Current |
Financial Performance of Lexicare Pharma.
Lexicare Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 93% increase. The company also saw a substantial improvement in profitability, with a 67.77% increase in profit. The company's net worth Soared by an impressive increase of 38.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lexicare Pharma?
In 2022, Lexicare Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Jul 2023 | ₹5.00 M | Open |
How Many Employees Work at Lexicare Pharma?
Unlock and access historical data on people associated with Lexicare Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lexicare Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lexicare Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
